Legitimate peptide therapies [like a GLP-1], intended for human use, require medical oversight, and must be dispensed through licensed pharmacies
Daily or twice-weekly dosing is unnecessary methionine, inositol, and choline have half-lives that support weekly administration, and more frequent dosing increases homocysteine and trimethylaminuria risk without additional metabolic benefit
According to the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) Obesity Clinical Practice Guidelines, weight loss medications should be considered as an adjunct to lifestyle therapy in all patients with T2DM as needed for weight loss sufficient to improve glycemic control, lipids, and blood pressure
This is structurally distinct from GHK alone, which lacks the copper ion that defines the GHK-Cu research compound
Patch testing prior to use is advised